RBC Capital Remains a Buy on Jazz Pharmaceuticals (JAZZ)

RBC Capital analyst Leonid Timashev maintained a Buy rating on Jazz Pharmaceuticals on April 6 and set a price target of $195.00. The company’s shares closed yesterday at $186.85.

Easter Sale - 70% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Timashev covers the Healthcare sector, focusing on stocks such as Exelixis, Cytokinetics, and Insmed. According to TipRanks, Timashev has an average return of 13.2% and a 48.00% success rate on recommended stocks.

Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $230.73.

Based on Jazz Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.2 billion and a net profit of $203.45 million. In comparison, last year the company earned a revenue of $1.09 billion and had a net profit of $191.12 million

Based on the recent corporate insider activity of 83 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JAZZ in relation to earlier this year. Last month, Patricia Carr, the SVP & CAO of JAZZ sold 2,723.00 shares for a total of $503,645.50.